OP-106 Horizon - Melflufen therapy for RRMM patients refractory to daratumumab and/or pomalidomide: Updated results and first report on PFS Meeting Abstract
| Authors: | Richardson, P.; Ocio, E.; Oriol, A.; Larocca, A.; Otero, P. R.; Moreb, J.; Blade, J.; Hassoun, H.; Cavo, M.; Alegre, A.; Mazumder, A.; Maisel, C.; Paner, A.; Gabrail, N.; Zonder, J. A.; Chauhan, D.; Harmenberg, J.; Thuresson, S.; Zubairand, H.; Mateos, M. V. |
| Abstract Title: | OP-106 Horizon - Melflufen therapy for RRMM patients refractory to daratumumab and/or pomalidomide: Updated results and first report on PFS |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837601309 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-113095 |
| Notes: | Meeting Abstract: 600 -- Source: Wos |
